Empowered Funds’s Supernus Pharmaceuticals SUPN Stock Holding History

Empowered Funds’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-47,093	Closed	-$1.68M	–	696
2022 Q4	$1.68M	Buy	+47,093	New	+$1.64M	0.11%	198

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Empowered Funds's SUPN Position: Q2 2026 in Review

Empowered Funds sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 5,107 shares — an estimated $264K sold.

Empowered Funds first reported a position in SUPN in Q1 2023 and held it in 6 quarters. The position peaked at $4.51M in Q1 2023. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Empowered Funds reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Empowered Funds sold 5,107 Supernus Pharmaceuticals shares in Q2 2026, an estimated $264K.
Empowered Funds first reported a position in Supernus Pharmaceuticals in Q1 2023 and held it in 6 quarters.
Empowered Funds's Supernus Pharmaceuticals position peaked at $4.51M in Q1 2023.
335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.